Mobile

A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-002078-23

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate and delineate the safety and efficacy profile of adalimumab (HUMIRA pre-filled syringe or HUMIRA pre-filled PEN) when administered to subjects with moderate to severe Crohn´s Disease.

Critère d'inclusion

  • Moderate to severe Crohn's Disease (Harvey Bradshaw Index score greater or equal to 7)

Liens